Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017, 23(14):3756-3768. Alisertib (MLN8237) purchased from Selleck.

  • Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

    Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

  • Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 NIS2cIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnSxNE42KM7:TR?= M1XzNFczKGh? NX7QWms6TE2VTx?= MlnSTWM2OD1yLkC0JO69VQ>? NGTWZVkzPjF|Nk[4OC=>
LS174T MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUiwMlUh|ryP MkPPO|IhcA>? MYXEUXNQ NEHHPZRKSzVyPUCuNFUh|ryP M{HIc|I3OTN4Nki0
T84 MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfkUHQxNjVizszN NHH1doY4OiCq NX\ldJV5TE2VTx?= NUftfYtvUUN3ME2wMlA6KM7:TR?= MWSyOlE{PjZ6NB?=
LS180 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[wOGcxNjVizszN MVi3NkBp NH60VGlFVVOR NHzoNVVKSzVyPUGg{txO M4LhW|I3OTN4Nki0
SW948 MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjjRoYxNjVizszN MoDRO|IhcA>? NWWxOWhQTE2VTx?= M4fGSWlEPTB;MTFOwG0> MV[yOlE{PjZ6NB?=
HCT15 M4fWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHtUHExNjVizszN MkXJO|IhcA>? NEHNZY9FVVOR MnPITWM2ODxyLkSg{txO MnHrNlYyOzZ4OES=
DLD-1 NFGyeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi4NE42KM7:TR?= M33pWlczKGh? Ml3lSG1UVw>? NYLwVZRMUUN3MEywMlgh|ryP NXPEeIxsOjZzM{[2PFQ>
MIP-101 NYfyN2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTnNE42KM7:TR?= NXfTXVY1PzJiaB?= NE\GSXZFVVOR MY\JR|UxRTFizszN MWGyOlE{PjZ6NB?=
SNU1544 NXTocJZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjNdIQxNjVizszN M{HjPFczKGh? M1rTc2ROW09? NUi5VY1uUUN3ME2xJO69VQ>? M2LXO|I3OTN4Nki0
OCI-Ly10 NFPRdnBEgXSxdH;4bYMhSXO|YYm= NEfv[4c4OiCq MV\EUXNQ NFfqUXpKSzVyPUCuNFU5KM7:TR?= MofTNlU5Pzh|M{G=
SU-DHL2 NEC4Oo1EgXSxdH;4bYMhSXO|YYm= NGH3VW04OiCq NGrO[WpFVVOR M3T3WWlEPTB;MD6wNUDPxE1? NEjncokzPTh5OEOzNS=>
OCI-LY7 M2HpWGN6fG:2b4jpZ{BCe3OjeR?= NI\Kd|I4OiCq MVzEUXNQ MXnJR|UxRTBwMEixJO69VQ>? NVS1SVVQOjV6N{izN|E>
SU-DHL6 NWntR2dPS3m2b4TvfIlkKEG|c3H5 NHPTc3o4OiCq Mo\QSG1UVw>? MWLJR|UxRTBwNEiyJO69VQ>? NX3kR2ROOjV6N{izN|E>
Jeko-1 NFW4PZpEgXSxdH;4bYMhSXO|YYm= M4Dnc|czKGh? NYT3RYl{TE2VTx?= MlvnTWM2OD1yLkCyPUDPxE1? Mm\PNlU5Pzh|M{G=
JVM-2 Mon2R5l1d3SxeHnjJGF{e2G7 NFW0OY84OiCq NFPsb4pFVVOR NF;LeIVKSzVyPUCuNFEh|ryP NEfxU5gzPTh5OEOzNS=>
Rec-1 M4\tTWN6fG:2b4jpZ{BCe3OjeR?= M3vFe|czKGh? NWXCboRXTE2VTx?= NF7vOGRKSzVyPUCuNFg4KM7:TR?= NHTFSowzPTh5OEOzNS=>
Z-138 M3vq[mN6fG:2b4jpZ{BCe3OjeR?= NYrMR4JHPzJiaB?= NEDTUI9FVVOR NGnybGlKSzVyPUCuNFE{KM7:TR?= NUDCU3hmOjV6N{izN|E>
H9 M1nRNGN6fG:2b4jpZ{BCe3OjeR?= Mlj1O|IhcA>? M{HjeGROW09? M1PDNmlEPTB;MD62JO69VQ>? MYGyOVg4QDN|MR?=
HH NXnG[FYzS3m2b4TvfIlkKEG|c3H5 NFHpeXg4OiCq NFTGfJhFVVOR MlPJTWM2OD1yLkeg{txO NHuzSIczPTh5OEOzNS=>
DND41 M3zuWWN6fG:2b4jpZ{BCe3OjeR?= M4\SW|czKGh? NXz1S|lXTE2VTx?= MYnJR|UxRTBwMTFOwG0> NEXKbXkzPTh5OEOzNS=>
CCL119 M1n5SmN6fG:2b4jpZ{BCe3OjeR?= NXXjcFlwPzJiaB?= NH[zWXFFVVOR NImwcJZKSzVyPUCuNFYzKM7:TR?= MYSyOVg4QDN|MR?=
J.Cam 1.6 MYTDfZRwfG:6aXOgRZN{[Xl? M3\KXFczKGh? NI[3c3RFVVOR NV\pPFNvUUN3ME2wMlExPSEQvF2= Moq5NlU5Pzh|M{G=
Sup-T1 NU[wTWdmS3m2b4TvfIlkKEG|c3H5 MXe3NkBp NGnY[FFFVVOR MXfJR|UxRTJwMUSyJO69VQ>? M{TtXVI2QDd6M{Ox
Tib 152 NWDP[Hd5S3m2b4TvfIlkKEG|c3H5 MXe3NkBp M13hTmROW09? Mlq4TWM2OD1yLkig{txO M3\aNVI2QDd6M{Ox
MCF7 NYWzSJRLTnWwY4Tpc44hSXO|YYm= MVW1JO69VQ>? M2Pne|I1KGh? M4TEVWROW09? NF\neYRKdmS3Y3XzJGczN01iYYLy[ZN1 MmjnNlU5OzR2MEG=
MDA-MB-231 MWPGeY5kfGmxbjDBd5NigQ>? Mn;4OUDPxE1? M1\hXFI1KGh? NVnZcW1lTE2VTx?= MV\JcoR2[2W|IFezM20h[XK{ZYP0 M13KUlI2QDN2NECx
MCF7 MXfGeY5kfGmxbjDBd5NigQ>? MmXxOUDPxE1? M2LsVVI1KGh? NI\sW|hFVVOR NIfIXHVF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy NHr3N5MzPTh|NESwNS=>
MCF7 NUmxOFZITnWwY4Tpc44hSXO|YYm= M2\yc|Uh|ryP NX;oRoxXOjRiaB?= MoW0SG1UVw>? MoPZSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|I> MUeyOVg{PDRyMR?=
MCF7 NIDIeGVHfW6ldHnvckBCe3OjeR?= NH\CToQ2KM7:TR?= NHPzcVIzPCCq M3q3TWROW09? NIPGO4xF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx NWrIPWVbOjV6M{S0NFE>
MCF7 NUH3eWN5TnWwY4Tpc44hSXO|YYm= MVG1JO69VQ>? MoPxNlQhcA>? NV;PeJplTE2VTx?= MnjBTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE> MWGyOVg{PDRyMR?=
MCF7 NIPoNGRHfW6ldHnvckBCe3OjeR?= NX;FUXo1PSEQvF2= NHywZlIzPCCq M4fjTmROW09? NWHGVZEzUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzPyCNaYCx M3fMT|I2QDN2NECx
MDA-MB-231 M2DadGZ2dmO2aX;uJGF{e2G7 NVnNV45HPSEQvF2= MlH1NlQhcA>? NVjSNI83TE2VTx?= NYjITm9pTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=> MoCxNlU5OzR2MEG=
MDA-MB-231 MYjGeY5kfGmxbjDBd5NigQ>? Ml;DNUDPxE1? NHPBSZEzPCCq MlS5SG1UVw>? MoTZTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|I> MkW1NlU5OzR2MEG=
MDA-MB-231 MVvGeY5kfGmxbjDBd5NigQ>? MUG1JO69VQ>? M2DXZ|I1KGh? Ml;qSG1UVw>? M2fVTWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG= NFLNXpkzPTh|NESwNS=>
MDA-MB-231 NGHR[HhHfW6ldHnvckBCe3OjeR?= NEPZbnI2KM7:TR?= M4i0[lI1KGh? NUHHOWJzTE2VTx?= NFKzZnFKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? NHXGTJgzPTh|NESwNS=>
MDA-MB-231 NIfE[XhHfW6ldHnvckBCe3OjeR?= NYixcIJOPSEQvF2= NWPmPHZFOjRiaB?= NYPmW|lQTE2VTx?= MlfuTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyO{BMcXBz NFvu[2ozPTh|NESwNS=>
MDA-MB-231 NHLufm9HfW6ldHnvckBCe3OjeR?= M3vYelUh|ryP MYqyOEBp NWfC[XZ5TE2VTx?= MWTJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEWz NUfhWWJ5OjV6M{S0NFE>
MCF7 M{jFS2Fxd3C2b4Ppd{BCe3OjeR?= M4PLWlUh|ryP NUnZWmgzOjRiaB?= NVTCW2R5TE2VTx?= M{TlT2lv\HWlZYOgZZBweHSxdHnjJIRm[XSq M2PM[|I2QDN2NECx
MDA-MB-231 MljKRZBweHSxc3nzJGF{e2G7 MWK1JO69VQ>? MV6yOEBp M2XndmROW09? M4T2fGlv\HWlZYOgZZBweHSxdHnjJIRm[XSq MVKyOVg{PDRyMR?=
MCF7 MlvtSpVv[3Srb36gRZN{[Xl? MkHtNUDPxE1? MkTCO|IhcA>? NH;FPJlFVVOR NGHFTHJKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= MYKyOVg{PDRyMR?=
MDA-MB-231 MXLGeY5kfGmxbjDBd5NigQ>? M2nFVFEh|ryP NYrXVmhZPzJiaB?= NXzPNohwTE2VTx?= NXzVVpd3UW6mdXPld{BifXSxcHjh[4lkKGSnYYTo M2Ww[FI2QDN2NECx
U-2 OS NVL2RYZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUC1NEDPxE1? NEDPfpMzPCCq MVnEUXNQ MWTJR|UxRTF4Lk[g{txO M4XINlI2Pzl{OEGx
MG-63 Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uzZlUxKM7:TR?= NG\IR4czPCCq NHnIZ4dFVVOR MWLJR|UxRTlwNTFOwG0> M3j5U|I2Pzl{OEGx
U-2 OS M4rvOmFxd3C2b4Ppd{BCe3OjeR?= MWO1JO69VQ>? M{\OTlI1KGh? M3y3emROW09? M4HmXWlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> MlzrNlU4QTJ6MUG=
MG-63 MkO2RZBweHSxc3nzJGF{e2G7 MoftOUDPxE1? MYeyOEBp MUfEUXNQ NWfOdopqUW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? MUCyOVc6OjhzMR?=
U-2 OS NF;NWGdHfW6ldHnvckBCe3OjeR?= M{TMXFUh|ryP M3i4[VI1KGh? NUPwS2RHTE2VTx?= NXjTVpJ7WHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq M3zvcFI2Pzl{OEGx
MG-63 NFjES45HfW6ldHnvckBCe3OjeR?= NYCyOXFNPSEQvF2= MnT3NlQhcA>? NF7EcldFVVOR NX\mWVNPWHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq NYD4cHd5OjV5OUK4NVE>
PANC-1 NVjtZ49pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;VOVAh|ryP NGi1O40zPCCq MVrEUXNQ M4jh[WlEPTB;Nz6xJO69VQ>? NGHxfpQzPTZ|MkKyOS=>
BxPC-3 NVfZb3BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnzbXFJPTBizszN NFqzNnUzPCCq Mn3KSG1UVw>? NX7xcIZ1UUN3ME22Mlgh|ryP MV[yOVY{OjJ{NR?=
PANC-1 MX3GeY5kfGmxbjDBd5NigQ>? MnTDOUDPxE1? M{DDXVI1KGh? Ml\kSG1UVw>? NUPnRY9mUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn MXeyOVY{OjJ{NR?=
BxPC-3 MUjGeY5kfGmxbjDBd5NigQ>? MmrpOUDPxE1? M1nlbFI1KGh? NVntV4x2TE2VTx?= NGTHXmpKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V? MVyyOVY{OjJ{NR?=
PANC-1 MUHGeY5kfGmxbjDBd5NigQ>? M33mUlUh|ryP NFPUZmUzPCCq Mli1SG1UVw>? MljTTY5lfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> M2HYTFI2PjN{MkK1
BxPC-3 M1HwWmZ2dmO2aX;uJGF{e2G7 MYe1JO69VQ>? MXmyOEBp NYnSeGlOTE2VTx?= M1PGPWlv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp MoLyNlU3OzJ{MkW=
SKOV3 MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfJTHEyODBizszN NEjRcFAzPCCq MWnEUXNQ NVPPd4hMUUN3ME2yNE41QCEQvF2= M3XLRVI2PjJ2N{Ww
OVCAR4 M1H4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[xNFAh|ryP MkTPNlQhcA>? Ml;mSG1UVw>? NVXCS4RsUUN3ME2yNk4yOyEQvF2= NYrCTmQ1OjV4MkS3OVA>
SKOV3 MlrwSpVv[3Srb36gRZN{[Xl? M1\xUFUh|ryP MV:3NkBp MXzEUXNQ MlfGTY5lfWOnczDHNk9OKGG{cnXzeC=> NFf4eWgzPTZ{NEe1NC=>
OVCAR4 NUeyNnV7TnWwY4Tpc44hSXO|YYm= Mon4OUDPxE1? M33LflczKGh? M33SOWROW09? MUHJcoR2[2W|IFeyM20h[XK{ZYP0 NFnZU2QzPTZ{NEe1NC=>
SKOV3 MV\BdI9xfG:|aYOgRZN{[Xl? MXW1JO69VQ>? MWOyOEBp M3\2RmROW09? MmfRTY5lfWOnczDhdI9xfG:|aYO= NIL5e2czPTZ{NEe1NC=>
OVCAR4 M2TRPGFxd3C2b4Ppd{BCe3OjeR?= MUG1JO69VQ>? M1O4NlI1KGh? MnfrSG1UVw>? NFrw[WNKdmS3Y3XzJIFxd3C2b4Ppdy=> MXWyOVYzPDd3MB?=
AGS MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H3WVI2KM7:TR?= NESydI4zPCCq NWXOVFNTTE2VTx?= Ml\YTWM2OD1zOT6wPUDPxE1? NHGwZ3QzPTZyOUmyNy=>
NCI-N78 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj6blUzPSEQvF2= Mlz4NlQhcA>? MlLUSG1UVw>? M{G2cmlEPTB;Mk[uN|Mh|ryP MoHNNlU3ODl7MkO=
AGS M{DzN2Fxd3C2b4Ppd{BCe3OjeR?= MojCOUDPxE1? NVv1coZXOjRiaB?= MkXySG1UVw>? NUK3VphuUW6mdXPld{BieG:ydH;zbZM> Mnf1NlU3ODl7MkO=
NCI-N78 NYG0UZNYSXCxcITvd4l{KEG|c3H5 MWS1JO69VQ>? MnfCNlQhcA>? MV7EUXNQ MUDJcoR2[2W|IHHwc5B1d3Orcx?= MoPTNlU3ODl7MkO=
AGS MkH0SpVv[3Srb36gRZN{[Xl? M{HVUlUh|ryP M3jxR|I1KGh? NUXmVXVXTE2VTx?= MUDJcoR2[2W|IITo[UBifXSxcHjh[5k> MVKyOVYxQTl{Mx?=
NCI-N78 MVvGeY5kfGmxbjDBd5NigQ>? NVu2c|R3PSEQvF2= Mm\DNlQhcA>? NEjTO2hFVVOR M37vNWlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? NWjxbotbOjV4MEm5NlM>
HSC-3 M{C5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPjTJpIOSEQvF2= Ml63OFghcA>? M2nsPWlEPTB;MD61OEDPxE1? NX\JR3lIOjV|Nk[xOFM>
GB30 M3\2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LMblEh|ryP NFHYOYE4KGR? NX;NRXlFTE2VTx?= NHfZXWJKSzVyPUCuNFEyKM7:TR?= MUOyOVExPjR{OB?=
GB9 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOxJO69VQ>? NYHaNZloPyCm NYq3b2R1TE2VTx?= MWnJR|UxRTBwMEK0JO69VQ>? MXSyOVExPjR{OB?=
GB169 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHnNUDPxE1? MoPjO{Bl MYjEUXNQ NFf5SWJKSzVyPUCuNFMzKM7:TR?= MoCwNlUyODZ2Mki=
T24 M135bmZ2dmO2aX;uJGF{e2G7 NVX6UHlxOSEQvF2= NUn6dYNMPDhiaB?= Ml\MSG1UVw>? Mn7nTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MXKyN|QxOzZ|Mx?=
RT4 Mn7tSpVv[3Srb36gRZN{[Xl? NFTqPJMyKM7:TR?= NUCwUIVpPDhiaB?= NFXBbIdFVVOR MlKxTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= M1HvUVI{PDB|NkOz
UM-UC-3 M3Lxe2Z2dmO2aX;uJGF{e2G7 M2PsbVEh|ryP M1Th[FQ5KGh? M{HQXWROW09? NHnWWYNKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NW\QN4p2OjN2MEO2N|M>
T24 MnHzRZBweHSxc3nzJGF{e2G7 Mkn6N{4yPiEQvF2= MlLRPVYhcA>? MlW5SG1UVw>? NVfZfZVQUUN3ME2wMlA{ODZizszN NVPLTmM{OjN2MEO2N|M>
RT4 NVPBNWlQSXCxcITvd4l{KEG|c3H5 NFj0cXE{NjF4IN88US=> MYe5OkBp MmXsSG1UVw>? M1q3[GlEPTB;MD6xNVk5KM7:TR?= NVrHW29kOjN2MEO2N|M>
UM-UC-3 M3XoZWFxd3C2b4Ppd{BCe3OjeR?= NGTCV5o{NjF4IN88US=> NEf1bo86PiCq NWLoXYtSTE2VTx?= Mn\kTWM2OD1yLkC0OFkh|ryP NGTHZ5UzOzRyM{[zNy=>
OVCAR-5 NXHxc5hnTnWwY4Tpc44hSXO|YYm= MUW1NEBvVQ>? NWLIVGxbUW6qaXLpeJMh[2WubDDtbYdz[XSrb36= MYeyN|M{PDN{Nx?=
SKOV3ip2 M3jwR2Z2dmO2aX;uJGF{e2G7 M4\5PFUxKG6P NFezeZRKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= Mmr2NlM{OzR|Mke=
S462 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHpXJYyODBizszN M2POTVczKGh? M{fXWWROW09? M2CzeGF1fGWwdXH0[ZMh[2WubDDndo94fGh? NFTifnozOzN{OEGxOC=>
2884 M1W1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorLNVAxKM7:TR?= NFvle404OiCq NYfLfJdETE2VTx?= NGfCXFRCfHSnboXheIV{KGOnbHyg[5Jwf3Sq M4n0WlI{OzJ6MUG0
2885 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrxW3h4OTByIN88US=> Mm\UO|IhcA>? NVvhdWQyTE2VTx?= MX7BeJRmdnWjdHXzJINmdGxiZ4Lve5Rp NHfJNHkzOzN{OEGxOC=>
CRL-2396 M1W0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTucYpkOTByIN88US=> NID6V|Z4[XSnch?= NULM[VdtUUN3ME2wMlA6OiEQvF2= MWmyN|E2OzV{NB?=
TIB-48 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G3UFExOCEQvF2= NUHDV484f2G2ZYK= NV\ISnV3UUN3ME2wMlA5QCEQvF2= M4PZSFI{OTV|NUK0
CRL-2396 NVzrdnJuS3m2b4TvfIlkKEG|c3H5 MofVNUDPxE1? NV7ZXotoPDhiaB?= NVLlXmYzf2G2ZYK= Moi1TY5lfWOnczDhdI9xfG:|aYO= NFLqdmszOzF3M{WyOC=>
TIB-48 NXjx[lkyS3m2b4TvfIlkKEG|c3H5 M33iVFEh|ryP MYi0PEBp NGfLZYd4[XSnch?= NH\5TIRKdmS3Y3XzJIFxd3C2b4Ppdy=> M{PCZ|I{OTV|NUK0
AGS NVTic3NSS3m2b4TvfIlkKEG|c3H5 NGXV[FAxNjVizszN M3HSRVI1KGh? MoXDSG1UVw>? MVrE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? NIT4ZVAzOjl5Mk[xNS=>
FLO-1 MmHWR5l1d3SxeHnjJGF{e2G7 NVrwSW85OC53IN88US=> NVXqUFZvOjRiaB?= MWTEUXNQ Mlf6SIVkemWjc3XzJINmdGxic4Xyeol3[Wx? M{C3RVIzQTd{NkGx
OE33 MVLDfZRwfG:6aXOgRZN{[Xl? Mk\3NE42KM7:TR?= NIDoV|czPCCq MXnEUXNQ MnrwSIVkemWjc3XzJINmdGxic4Xyeol3[Wx? MnnGNlI6PzJ4MUG=
SKLMS MUTDfZRwfG:6aXOgRZN{[Xl? NFfuTFY4PSCwTR?= MV65OkBp M2WyS2lv\HWlZYOgZZBweHSxc3nz M2PVWFIzQDJzOUm3
Leio285 MYXDfZRwfG:6aXOgRZN{[Xl? MWi3OUBvVQ>? Mli1PVYhcA>? NUfWbIZ[UW6mdXPld{BieG:ydH;zbZM> MWCyNlgzOTl7Nx?=
Mes-Sa NULQWWZRS3m2b4TvfIlkKEG|c3H5 MlvIO|Uhdk1? NUDRR5h5QTZiaB?= NXnuVGpRUW6mdXPld{BieG:ydH;zbZM> MWmyNlgzOTl7Nx?=
DAOY M1LVWmN6fG:2b4jpZ{BCe3OjeR?= NXzBOWdvOTBizszN NVeyclJ2PzJiaB?= NH7IOZNFVVOR MoLjTWM2OD1yLkC0JO69VQ>? NIW3SHkzOjZ4OUOzOS=>
IMR32 MVPDfZRwfG:6aXOgRZN{[Xl? M1vCVFExKM7:TR?= MYG3NkBp MWDEUXNQ NYTTblc6UUN3ME2wMlA{KM7:TR?= MkHKNlI3Pjl|M{W=
Molt-4 MmfLR5l1d3SxeHnjJGF{e2G7 M1TGfVExKM7:TR?= M361OVczKGh? MVXEUXNQ Mnv6TWM2OD1yLkCyJO69VQ>? NV;GdY94OjJ4NkmzN|U>
MOLM-13 NYT3UnV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonwN{DPxE1? MnnVO|IhcA>? MorBSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NXnsR5RPOjJ2OEiyOFk>
HL-60 MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfGN{DPxE1? MmXuO|IhcA>? NIfLco5FcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NIiwOZYzOjR6OEK0PS=>
MV4-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCzJO69VQ>? Mn;XO|IhcA>? NH7qUWNFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NXTE[IJFOjJ2OEiyOFk>
SKM-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL4dok{KM7:TR?= MoLWO|IhcA>? MWPEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 M3ftXlIzPDh6MkS5
SH2 NFfXS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDwZVQ3OyEQvF2= M4jaZ|czKGh? MnexSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MmjTNlI1QDh{NEm=
NOMO-1 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK4T|U{KM7:TR?= NIi4clM4OiCq NVjVW5NiTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MoTGNlI1QDh{NEm=
OCL-AML2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLMWpQ{KM7:TR?= MoO0O|IhcA>? NInqNHdFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MVGyNlQ5QDJ2OR?=
PL-21 NWDFUGZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLWN{DPxE1? MVG3NkBp NF3Mb2NFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 M4DKdlIzPDh6MkS5
KG-1 M2Psdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPiV5Q{KM7:TR?= NF7NcVE4OiCq MmjRSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MkLENlI1QDh{NEm=
A172 NF3UZYZEgXSxdH;4bYMhSXO|YYm= NIHycYkyODBizszN M17GZVI1KGh? MoHoSG1UVw>? NEfZbplKSzVyPUCuNVIxKM7:TR?= Mo\JNlIzPzR|OUm=
U87 M2HTbmN6fG:2b4jpZ{BCe3OjeR?= NE\tXYEyODBizszN NX7JTmI5OjRiaB?= MlLkSG1UVw>? MlHkTWM2OD1yLkGwOUDPxE1? NFHHfWgzOjJ5NEO5PS=>
U251 MVTDfZRwfG:6aXOgRZN{[Xl? M3TjNFExOCEQvF2= MUOyOEBp M2HJNmROW09? M2TWSGlEPTB;MD6xNFAh|ryP M3ruVFIzOjd2M{m5
T98 NGXydYZEgXSxdH;4bYMhSXO|YYm= NEP0WFIyODBizszN M4D0NFI1KGh? MlHXSG1UVw>? M4DDdmlEPTB;MD6xNlUh|ryP MkTSNlIzPzR|OUm=
LN18 NX;hV5VSS3m2b4TvfIlkKEG|c3H5 MVKxNFAh|ryP MoHmNlQhcA>? MXnEUXNQ MXHJR|UxRTBwMkGwJO69VQ>? NFjHfnczOjJ5NEO5PS=>
LN443 NHLxd2lEgXSxdH;4bYMhSXO|YYm= MUCxNFAh|ryP M3jBclI1KGh? MkW4SG1UVw>? MY\JR|UxRTBwMkKwJO69VQ>? MlPjNlIzPzR|OUm=
HF66 MonQR5l1d3SxeHnjJGF{e2G7 MV[xNFAh|ryP NVKwS25qOjRiaB?= NVjIdWpWTE2VTx?= MV3JR|UxRTBwMkK1JO69VQ>? MmHCNlIzPzR|OUm=
HF2303 M4LTVWN6fG:2b4jpZ{BCe3OjeR?= Ml7PNVAxKM7:TR?= NILSXZQzPCCq M2TrXmROW09? M3H0[WlEPTB;MD6wOlAh|ryP M1jVcFIzOjd2M{m5
HF2359 M3eyPGN6fG:2b4jpZ{BCe3OjeR?= M2G1UlExOCEQvF2= M{TZR|I1KGh? M1e0XmROW09? M4rWZmlEPTB;MD6wOlAh|ryP M2X1PFIzOjd2M{m5
HF2414 NYPEN2xNS3m2b4TvfIlkKEG|c3H5 NYKxWVY{OTByIN88US=> NY\DW3JiOjRiaB?= NIi5NllFVVOR MoXNTWM2OD1yLkC4NEDPxE1? NFnM[2IzOjJ5NEO5PS=>
A-673 NETqbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnOWIt3OTBizszN M{\Edlk3KGh? MoD2SG1UVw>? NEXWNGRKSzVyPUCuNFMzKM7:TR?= MXWyNVQ1QDV7MR?=
TC-32 NHjk[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvsNVAh|ryP MoXvPVYhcA>? M1zmTmROW09? MmTDTWM2OD1yLkCzPUDPxE1? NYDkNXRVOjF2NEi1PVE>
TC-71 NWXobIxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqxNEDPxE1? MnfUPVYhcA>? MmP0SG1UVw>? NHXnSIJKSzVyPUCuNVAzKM7:TR?= NYPqe5ptOjF2NEi1PVE>
SK-N-MC NVXI[3JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPxenhLOTBizszN NIjz[FE6PiCq NV7wTo1tTE2VTx?= MlH5TWM2OD1yLkC3NkDPxE1? NGnUd2QzOTR2OEW5NS=>
CHLA-9 NFL3cYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzGT|I2OTBizszN MmezPVYhcA>? NYHvUmlETE2VTx?= MWPJR|UxRTBwMEG4JO69VQ>? MlvKNlE1PDh3OUG=
CHLA-10 Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;t[VEyOCEQvF2= M2HZZVk3KGh? M1riTmROW09? NHPRXlJKSzVyPUCuNFYxKM7:TR?= NX3VcXlOOjF2NEi1PVE>
CHLA-25 M3\nbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPkNVAh|ryP Mn3KPVYhcA>? NH\OXoNFVVOR MVPJR|UxRTBwMU[4JO69VQ>? MkTINlE1PDh3OUG=
CHLA-32 Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonmNVAh|ryP NVzUZZJvQTZiaB?= MVXEUXNQ NWm0eWRnUUN3ME2wMlE{PiEQvF2= Ml7JNlE1PDh3OUG=
CHLA-56 NEC0VYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqxNEDPxE1? NH;uWog6PiCq NWT2NHh5TE2VTx?= NUPDd3pGUUN3ME2xNEDPxE1? M2DXNFIyPDR6NUmx
CHLA-258 NVfZ[GNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3nNVAh|ryP MV[5OkBp NXrrWFdJTE2VTx?= MYPJR|UxRTBwMUOyJO69VQ>? NWnmeZlZOjF2NEi1PVE>
COG-E-352 M2\6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rmUFExKM7:TR?= NVTMb5h{QTZiaB?= Mny1SG1UVw>? MYDJR|UxRTBwMESzJO69VQ>? MkfSNlE1PDh3OUG=
CHLA-90 M4XySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHTU5B3OTBizszN MUK5OkBp MWXEUXNQ M4[zW2lEPTB;MD6wOlEh|ryP MonwNlE1PDh3OUG=
CHLA-119 M1rM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTYXGRsOTBizszN MUG5OkBp MVTEUXNQ MVnJR|UxRTBwMEKyJO69VQ>? M{nWOFIyPDR6NUmx
CHLA-122 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGxNEDPxE1? MWK5OkBp MX;EUXNQ NHH6RZJKSzVyPUCuNFE6KM7:TR?= NFvK[JUzOTR2OEW5NS=>
CHLA-136 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TCVVExKM7:TR?= MVS5OkBp NYTWTnE3TE2VTx?= MV7JR|UxRTBwMEO5JO69VQ>? MUCyNVQ1QDV7MR?=
CHLA-140 NECxO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDuUmYyOCEQvF2= NXzvfopxQTZiaB?= M{WwV2ROW09? MnrkTWM2OD1yLkCyOkDPxE1? MWSyNVQ1QDV7MR?=
LA-N-6 MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK1O4MyOCEQvF2= MUC5OkBp Moq0SG1UVw>? Mny1TWM2OD1yLkC1OEDPxE1? NUOweZdQOjF2NEi1PVE>
NB-1643 NIXvZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fmTlExKM7:TR?= NIHOeG46PiCq MnHOSG1UVw>? MmGwTWM2OD1yLkCzO{DPxE1? NGTQWG8zOTR2OEW5NS=>
NB-EBc1 NVTGNXp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKxNEDPxE1? NHvMcnE6PiCq M3HIfmROW09? Ml[wTWM2OD1yLkC1NEDPxE1? NI\pdlIzOTR2OEW5NS=>
SK-N-BE-1 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2xNEDPxE1? NUfGNJZbQTZiaB?= MmPYSG1UVw>? NXPjSVZ6UUN3ME2wMlAzQCEQvF2= NV34R402OjF2NEi1PVE>
SK-N-BE-2 NYHx[|RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX61R3dMOTBizszN NIXj[WY6PiCq M{PJbWROW09? NWDCVHNnUUN3ME2wMlA{PiEQvF2= NXHIU2FCOjF2NEi1PVE>
SMS-KAN MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnkXXcyOTBizszN M37aOVk3KGh? NFTTTI1FVVOR NXGxRXVVUUN3ME2wMlA{PCEQvF2= MnvhNlE1PDh3OUG=
SMS-KANR NIHmdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HwVVExKM7:TR?= MWO5OkBp M2Hx[2ROW09? MXHJR|UxRTBwMEK2JO69VQ>? MUmyNVQ1QDV7MR?=
SMS-KCN MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILseIUyOCEQvF2= M3\TRlk3KGh? MlzaSG1UVw>? NGDRV2RKSzVyPUCuNFE6KM7:TR?= Mkn1NlE1PDh3OUG=
SMS-KCNR NVLXZ5U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWxNEDPxE1? M3TQdVk3KGh? MlTqSG1UVw>? NEn0[|BKSzVyPUCuNFExKM7:TR?= NXLnNWx5OjF2NEi1PVE>
SMS-LHN MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i1PVExKM7:TR?= NWrBW3ljQTZiaB?= MYHEUXNQ NV3VbnVbUUN3ME2wMlA{OiEQvF2= M2\qdVIyPDR6NUmx
SMS-MSN NVT2TG9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XNbFExKM7:TR?= M{nGbVk3KGh? M3;mc2ROW09? M3j0ZWlEPTB;MD6wNlIh|ryP NHPWS4ozOTR2OEW5NS=>
SMS-SAN M{jLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\BNVAh|ryP MWS5OkBp NGnpNlZFVVOR Ml7lTWM2OD1yLkCyNEDPxE1? NEDIZpIzOTR2OEW5NS=>
Granta-4 MWnDfZRwfG:6aXOgRZN{[Xl? NF\nXpQyOCEQvF2= NYLCVWRpPyCm M4DrdmlEPTB;MD6wOFAh|ryP MXqyNVI6OTh4Nx?=
DB M3u5dGN6fG:2b4jpZ{BCe3OjeR?= NYj1U4dnOTBizszN NIfBNJE4KGR? M{TRU2lEPTB;MD6wOFIh|ryP NYW0fXpVOjF{OUG4Olc>
RL NF\LOWVEgXSxdH;4bYMhSXO|YYm= MWOxNEDPxE1? M4Ha[Fch\A>? NGmyWnhKSzVyPUCuNFE2KM7:TR?= MnP0NlEzQTF6Nke=
K562 NH76V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTrNVAh|ryP NV\uR493QTZiaB?= NWrQNJZoUUN3ME2wMlA5PyEQvF2= NUP4WVVTOjFyOUG2N|M>
LAMA-84 M4HQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLMWVUyOCEQvF2= NWK3PWZXQTZiaB?= M2O1S2lEPTB;MD6wOVch|ryP MUWyNVA6OTZ|Mx?=
MM15 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PvdFQh|ryP MXW3NkBp NI\OPWdFVVOR NUTybGFPUUN3ME2wMlE{KM7:TR?= M4GyOFIxOzh{OES0
OPM1 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW0JO69VQ>? NYnBN3FkPzJiaB?= NVfOO2w6TE2VTx?= MWfJR|UxRTBwMEOg{txO NX7mZWtCOjB|OEK4OFQ>
RPM1 NFnsSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DYSFQh|ryP MmfPO|IhcA>? MkWzSG1UVw>? MoPTTWM2OD1zMD6zNkDPxE1? MXyyNFM5Ojh2NB?=
INA6 NWH4ZnRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF62OI01KM7:TR?= NFXOOJg4OiCq M4fTU2ROW09? MkP2TWM2OD1yLkCwNkDPxE1? NH\DUIszODN6Mki0OC=>
OPM2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXWOEDPxE1? MWi3NkBp MlTDSG1UVw>? NIL4XZpKSzVyPUSuN|ch|ryP NEPESIwzODN6Mki0OC=>
MM1R MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXNSoJQPCEQvF2= MXS3NkBp M{PMUWROW09? MVTJR|UxRTFwNkig{txO NYLHbnVTOjB|OEK4OFQ>
DOX40 M2jGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXG0JO69VQ>? MYW3NkBp M4PSOmROW09? M4[1c2lEPTB;NT60PEDPxE1? M3jCRlIxOzh{OES0
LR5 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37u[VQh|ryP M2TrNlczKGh? MU\EUXNQ M{\KeWlEPTB;Mj61N{DPxE1? MYCyNFM5Ojh2NB?=
U266 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Hl[|Qh|ryP NFXRe2w4OiCq NEnOXI5FVVOR M1r6bmlEPTB;MT60N{DPxE1? MXKyNFM5Ojh2NB?=
RD Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLGNVAh|ryP MXS5OkBp NUWwOJlEUUN3ME2wMlIzQCEQvF2= M4rBe|IxOTB6M{O4
Rh41 NWi3OJdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfqNVAh|ryP NEXzS2k6PiCq Mlj3TWM2OD1yLkC5NEDPxE1? MXWyNFExQDN|OB?=
Rh30 NILRPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorjNVAh|ryP MlrYPVYhcA>? Mor3TWM2OD1yLkKzNEDPxE1? NXPYNI9YOjBzMEizN|g>
BT-12 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLuRnUyOCEQvF2= NFqzeXQ6PiCq M1\uXGlEPTB;MD6wOlAh|ryP MnviNlAyODh|M{i=
CHLA-266 NYj0cJFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvt[5IyOCEQvF2= NIDHdIY6PiCq NV7yTFlNUUN3ME2wMlA4OiEQvF2= M1PoUlIxOTB6M{O4
TC-71 NXu0XlAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfJNVAh|ryP MmDyPVYhcA>? MmXtTWM2OD1yLkGwNkDPxE1? MYOyNFExQDN|OB?=
SJ-GBM2 NF7w[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTVNVAh|ryP NYH3UWxzQTZiaB?= NGDTcHBKSzVyPUCuNFUxKM7:TR?= MVyyNFExQDN|OB?=
NALM-6 M2TxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUexNEDPxE1? MljCPVYhcA>? MXTJR|UxRTBwME[yJO69VQ>? Mnv1NlAyODh|M{i=
COG-LL-317 NGLXd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\2VoFROTBizszN MXS5OkBp MWrJR|UxRTBwMES3JO69VQ>? MVyyNFExQDN|OB?=
RS4-11 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrXNVAh|ryP Mn3kPVYhcA>? NGrYTnZKSzVyPUCuNFE5KM7:TR?= NHXEToUzODFyOEOzPC=>
MOLT-4 NUHGfHd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v5cFExKM7:TR?= MWW5OkBp NXfVS4NQUUN3ME2wMlAzPiEQvF2= NFf0cWQzODFyOEOzPC=>
CCRF-CEM NHmwN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnZVHYyOCEQvF2= MkHZPVYhcA>? MV\JR|UxRTBwMEm0JO69VQ>? M4nw[lIxOTB6M{O4
Kasumi-1 NIrO[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LofFExKM7:TR?= M4P0Olk3KGh? NE\VbYhKSzVyPUCuNVA{KM7:TR?= NYPWR5Y5OjBzMEizN|g>
Karpas-299 NI\O[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LQblExKM7:TR?= MYO5OkBp NYr1VYpHUUN3ME2wMlA{QCEQvF2= M2DyTVIxOTB6M{O4
Ramos-RA1 Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7PdJFuOTBizszN MlHXPVYhcA>? M4j6Z2lEPTB;MD6xNlch|ryP NVHQVldHOjBzMEizN|g>

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+30% PEG300+5%Tween-80+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Recruiting Estrogen Receptor Status|HER2/Neu Negative|Invasive Breast Carcinoma|Postmenopausal|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) July 6 2017 Phase 2
NCT02860000 Recruiting Estrogen Receptor Status|HER2/Neu Negative|Invasive Breast Carcinoma|Postmenopausal|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) July 6 2017 Phase 2
NCT02700022 Terminated Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals Inc. October 2016 Phase 1
NCT02700022 Terminated Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals Inc. October 2016 Phase 1
NCT02812056 Withdrawn Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals Inc. September 2016 Phase 1
NCT02812056 Withdrawn Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals Inc. September 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products5

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID